Three Global Leaders Near Buy Points With Earnings Ahead

Fabrinet reports on Monday.

Investors Business Daily • Feb 2, 2026

LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results on Wed., Feb. 25, 2026, at 1 p.m. London time (8 a.m. Eastern Standard Time). The Company will release its fourth-quarter and full-year 2025 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to.

Business Wire • Jan 20, 2026

LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

LivaNova to Present at J.P. Morgan Healthcare Conference in January

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pacific Standard Time. The discussion will be available to all interested parties who register to attend the webcast, w.

Business Wire • Dec 23, 2025

LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting

LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses. “At the heart of LivaNova's purpose as a Comp.

Business Wire • Dec 3, 2025

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. “Lucile is an accomplished healthcare executive with more than 25 years of leadership in the medtech sector,” Makatsaria said. “With her extensive OSA.

Business Wire • Dec 2, 2025

LivaNova to Present at Piper Sandler Healthcare Conference in December

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible.

Business Wire • Nov 25, 2025

LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services

LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assigned VNS Therapy™, a LivaNova neuromodulation treatment for patients 4 years of age and older with Drug-Resistant Epilepsy (DRE) and focal seizures, to New Technology Ambulatory Payment Classification (APC) 1580 for new patient implants (NPIs) under the 2026 Medicare Hospital Outpatient Prospective Payment System.

Business Wire • Nov 24, 2025

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range financial plan. “We are confident in our ability to deliver on the targets we outlined today. LivaNova's talented team is focused on a revitalized innovation strategy and operational excellence,” said Vladimir Makatsaria, Chief Executive Officer of LivaNova. “The leadership positions we hold in our.

Business Wire • Nov 12, 2025

LivaNova PLC (LIVN) Q3 2025 Earnings Call Transcript

LivaNova PLC ( LIVN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Vladimir Makatsaria - CEO & Director Alex Shvartsburg - Chief Financial Officer Ahmet Tezel - Chief Innovation Officer Conference Call Participants Michael Polark - Wolfe Research, LLC Adam Maeder - Piper Sandler & Co., Research Division Matthew Taylor - Jefferies LLC, Research Division Anthony Petrone - Mizuho Americas LLC David Rescott - Robert W. Baird & Co. Incorporated, Research Division Michael Matson - Needham & Company, LLC, Research Division John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to LivaNova plc Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 5, 2025